首页> 外文期刊>British journal of ophthalmology >Recombinant tissue plasminogen activator in cases with fibrin formation after cataract surgery: a prospective randomised multicentre study.
【24h】

Recombinant tissue plasminogen activator in cases with fibrin formation after cataract surgery: a prospective randomised multicentre study.

机译:白内障手术后纤维蛋白形成的重组组织纤溶酶原激活物:一项前瞻性随机多中心研究。

获取原文
获取原文并翻译 | 示例
       

摘要

AIMS: This study investigated the effect of tissue plasminogen activator (tPA) in patients with severe intracameral fibrin after extracapsular cataract extraction or phacoemulsification with posterior chamber intraocular lens implantation. METHODS: A randomised prospective multicentre study was carried out in 86 patients with intraocular fibrin formation 2-8 days after cataract surgery. While the first group (n = 41) received only anti-inflammatory drugs, a single anterior chamber injection of tPA (10 micrograms) as an additional treatment to the standard was given in the second group (n = 44). On days 1, 2, 14, and 90 after randomisation, the visual acuities, slit lamp findings, and intraocular pressures were documented in standardised protocols. Efficacy of treatment was judged by the rate of fibrinolysis (primary objective), the frequency of synechiae, and central capsular fibrosis (secondary objectives). RESULTS: The incidence and quantity of intraocular fibrin were significantly lower in the patients treated with tPA than in the control group (p < 0.05). The frequencies of synechiae were reduced by tPA injection. The capsule fibrosis noted after 3 months was significantly lower in the tPA group (p = 0.027). No ocular side effects were noted after the tPA injections. CONCLUSIONS: Lysis of postcataract fibrin formation is accelerated and increased by a single intracameral injection of 10 micrograms tPA in addition to standard anti-inflammatory treatment. The findings suggest that the tPA injection reduces posterior capsule fibrosis, which still has to be addressed in larger study populations and with a long term follow up.
机译:目的:本研究调查了组织纤维蛋白溶酶原激活剂(tPA)在严重白内障后囊外白内障摘除或超声乳化联合后房人工晶状体植入术中对重度前房纤维蛋白患者的作用。方法:对白内障手术后2-8天的86例眼内纤维蛋白形成患者进行了一项前瞻性随机多中心研究。第一组(n = 41)仅接受抗炎药,而第二组(n = 44)则单次tPA前房注射(10微克)作为对标准的补充治疗。在随机分组后的第1、2、14和90天,以标准化方案记录视力,裂隙灯发现和眼内压。通过纤维蛋白溶解率(主要目标),粘连的发生频率和中央包膜纤维化(次要目标)来判断治疗的有效性。结果:tPA治疗的患者眼内纤维蛋白的发生率和数量均显着低于对照组(p <0.05)。通过tPA注射减少了粘连的频率。 tPA组3个月后发现的胶囊纤维化明显降低(p = 0.027)。 tPA注射后未观察到眼部副作用。结论:除标准抗炎治疗外,单次前房内注射10微克tPA可以加速并增加白内障后纤维蛋白形成的溶解。研究结果表明,tPA注射可减少后囊纤维化,这在较大的研究人群中仍需解决,并需要长期随访。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号